Cargando…
CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement
Warfarin is a frequently prescribed anticoagulant in rehabilitation patients. Adverse drug reactions of warfarin were reported as bleeding and cutaneous microvascular thrombosis. Major bleeding, such as intracranial hemorrhage and psoas hematoma, in patients receiving anticoagulation therapy is a ra...
Autores principales: | Kim, Young Bum, Ko, Moon Ju, Lee, Dae Gu, Do, Jong Gul, Hwang, Ji Hye |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Academy of Rehabilitation Medicine
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546190/ https://www.ncbi.nlm.nih.gov/pubmed/23342320 http://dx.doi.org/10.5535/arm.2012.36.6.857 |
Ejemplares similares
-
A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
por: Lee, Soo-Youn, et al.
Publicado: (2005) -
The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016) -
A Case Report of a Patient Carrying CYP2C9*3/4 Genotype with Extremely Low Warfarin Dose Requirement
por: Lee, Soo-Youn, et al.
Publicado: (2007) -
VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013) -
Characterizing variability in warfarin dose requirements in children using modelling and simulation
por: Hamberg, Anna-Karin, et al.
Publicado: (2014)